8-K

v200593_8k.htm

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES

EXCHANGE ACT OF 1934

Date of

report (Date of earliest event reported): November 2, 2010

PFIZER

INC.

(Exact

name of registrant as specified in its charter)

Delaware

1-3619

13-5315170

(State

or other

(Commission

File

(I.R.S.

Employer

jurisdiction

of

(Number)

Identification

No.)

incorporation)

235

East 42nd Street

10017

New

York, New York

(Zip

Code)

(Address

of principal executive offices)

Registrant's

telephone number, including area code:

(212)

733-2323

Not

Applicable

(Former

Name or Former Address, if changed since last report)

Check the

appropriate box below if the Form 8-K filing is intended to simultaneously

satisfy the obligation of the registrant under any of the following provisions

(see General Instruction A.2. below):

Written communication pursuant to Rule 425 under the Securities Act (17 CFR

230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR

240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

(17 CFR 240.14d-2 (b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

(17 CFR 240.13e-4(c))

Item 2.02

Results of Operations and Financial Condition

On

November 2, 2010, Pfizer Inc. ( Pfizer ) issued a press release announcing its

financial results for the third quarter of 2010. The information contained in

the press release is deemed to be filed under the Securities Exchange Act of

1934 as Exhibit 99 to this report, and such press release is incorporated herein

by reference.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

Exhibit

99 -

Press

Release of Pfizer Inc. dated November 2, 2010, reporting Pfizer's

financial results for the third quarter of 2010. Exhibit

99 is deemed to be filed under the Securities Exchange Act of 1934 in

this Current Report on Form 8-K.

SIGNATURE

Under the

requirements of the Securities Exchange Act of 1934, the registrant has caused

this report to be signed on its behalf by the authorized

undersigned.

PFIZER

INC.

By:

/s/ Matthew Lepore

Matthew

Lepore

Vice

President, Chief Counsel Corporate Governance,

and

Assistant General Counsel

Dated:

November 2, 2010

EXHIBIT

INDEX

Exhibit

No.

Description

99

Press

Release of Pfizer Inc. dated November 2, 2010, reporting Pfizer's

financial results for the third quarter of

2010.